Atossa Genetics Inc. (NASDAQ:ATOS) Sees Large Increase in Short Interest

Atossa Genetics Inc. (NASDAQ:ATOS) saw a large growth in short interest in December. As of December 15th, there was short interest totaling 2,284,050 shares, a growth of 47.0% from the November 30th total of 1,554,063 shares. Currently, 1.9% of the shares of the stock are short sold. Based on an average daily volume of 1,461,615 shares, the short-interest ratio is currently 1.6 days. Based on an average daily volume of 1,461,615 shares, the short-interest ratio is currently 1.6 days. Currently, 1.9% of the shares of the stock are short sold.

Institutional Trading of Atossa Genetics

Several institutional investors have recently made changes to their positions in ATOS. Ameriprise Financial Inc. acquired a new position in Atossa Genetics in the second quarter valued at approximately $2,468,000. Jane Street Group LLC purchased a new stake in Atossa Genetics in the second quarter valued at $381,000. Y Intercept Hong Kong Ltd purchased a new stake in Atossa Genetics in the second quarter valued at $321,000. Qube Research & Technologies Ltd lifted its stake in shares of Atossa Genetics by 357.4% in the 2nd quarter. Qube Research & Technologies Ltd now owns 416,374 shares of the company’s stock valued at $346,000 after purchasing an additional 325,340 shares during the last quarter. Finally, GSA Capital Partners LLP grew its holdings in shares of Atossa Genetics by 509.0% during the 3rd quarter. GSA Capital Partners LLP now owns 310,754 shares of the company’s stock worth $269,000 after purchasing an additional 259,725 shares during the period. Hedge funds and other institutional investors own 12.74% of the company’s stock.

Atossa Genetics Stock Down 4.0%

NASDAQ ATOS opened at $0.66 on Monday. Atossa Genetics has a 52 week low of $0.55 and a 52 week high of $1.29. The business’s fifty day simple moving average is $0.80 and its 200-day simple moving average is $0.84. The firm has a market cap of $85.11 million, a PE ratio of -2.75 and a beta of 0.95.

Atossa Genetics (NASDAQ:ATOS) last announced its quarterly earnings data on Wednesday, November 12th. The company reported ($0.07) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.07). Research analysts expect that Atossa Genetics will post -0.22 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on ATOS shares. Ascendiant Capital Markets upped their target price on shares of Atossa Genetics from $7.75 to $8.00 and gave the stock a “buy” rating in a report on Monday, December 8th. Zacks Research lowered shares of Atossa Genetics from a “hold” rating to a “strong sell” rating in a research report on Monday, October 13th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Atossa Genetics in a research note on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, Atossa Genetics currently has a consensus rating of “Hold” and an average price target of $6.33.

Atossa Genetics Company Profile

Atossa Genetics, Inc is a clinical-stage biotechnology company based in Seattle, Washington, focused on developing therapeutics and diagnostic products for breast cancer and other breast-related conditions. The company’s mission centers on delivering targeted, minimally invasive solutions that address early detection, treatment, and prevention in women at risk for or diagnosed with breast malignancies.

The company’s pipeline includes Z-Endoxifen, an oral formulation of endoxifen designed to treat and prevent estrogen receptor–positive breast cancers, particularly in patients with ductal carcinoma in situ or those at high risk of recurrence.